<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="93582"><DrugName>vaborbactam + meropenem (iv, Gram-negative bacterial infections), Melinta Therapeutics/ Menarini</DrugName><DrugNamesKey><Name id="43046128">Carbavance</Name><Name id="43106446">Vabomere</Name></DrugNamesKey><DrugSynonyms><Name><Value>RPX-7009 + meropenem (iv, Gram-negative bacterial infections) Rempex Pharmaceuticals</Value></Name><Name><Value>RPX-7009 + meropenem</Value></Name><Name><Value>Carbavance</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>vaborbactam + meropenem</Value></Name><Name><Value>vaborbactam + meropenem (iv, Gram-negative bacterial infections) Rempex Pharmaceuticals</Value></Name><Name><Value>Vabomere</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>vaborbactam + meropenem (iv, Gram-negative bacterial infections), Melinta Therapeutics</Value></Name><Name><Value>vaborbactam + meropenem (iv, Gram-negative bacterial infections), Melinta Therapeutics/ Menarini</Value></Name><Name><Value>96036-03-2</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>1360457-46-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1066034">Rempex Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company id="29298">Melinta Therapeutics Inc</Company><Company id="18053">The Menarini Group</Company></CompaniesPrimary><CompaniesSecondary><Company id="1066034">Rempex Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1066034" type="Company"><TargetEntity id="5035416904" type="organizationId">Rempex Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="18053" type="Company"><TargetEntity id="4296446248" type="organizationId">A Menarini Industrie Farmaceutiche Riunite Srl</TargetEntity></SourceEntity><SourceEntity id="29298" type="Company"><TargetEntity id="4296686682" type="organizationId">Melinta Subsidiary Corp</TargetEntity></SourceEntity><SourceEntity id="137" type="ciIndication"><TargetEntity id="D016905" type="MeSH"/><TargetEntity id="-409642348" type="omicsDisease"/><TargetEntity id="801" type="siCondition"/></SourceEntity><SourceEntity id="1815" type="ciIndication"><TargetEntity id="J15" type="ICD10"/><TargetEntity id="10060946" type="MEDDRA"/><TargetEntity id="D018410" type="MeSH"/><TargetEntity id="-2031977293" type="omicsDisease"/><TargetEntity id="928" type="siCondition"/></SourceEntity><SourceEntity id="284" type="ciIndication"><TargetEntity id="10037596" type="MEDDRA"/><TargetEntity id="D011704" type="MeSH"/><TargetEntity id="-721934222" type="omicsDisease"/><TargetEntity id="344" type="siCondition"/></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"/><TargetEntity id="10060945" type="MEDDRA"/><TargetEntity id="D001424" type="MeSH"/><TargetEntity id="-1693440076" type="omicsDisease"/><TargetEntity id="800" type="siCondition"/></SourceEntity><SourceEntity id="86" type="Action"><TargetEntity id="501" type="Mechanism">beta-Lactamase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Complicated urinary tract infection - US - Nov-2017</FirstLaunched><FirstLaunched>Pyelonephritis - US - Nov-2017</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="137">Gram negative bacterium infection</Indication><Indication id="1815">Bacterial pneumonia</Indication><Indication id="284">Pyelonephritis</Indication><Indication id="3898">Complicated urinary tract infection</Indication><Indication id="40">Bacterial infection</Indication></IndicationsPrimary><ActionsPrimary><Action id="86">Beta lactamase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="4855">Antibacterial multidrug resistance inhibitor</Action><Action id="73547">Carbapenem</Action></ActionsSecondary><Technologies><Technology id="175">Drug combination</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="66">Antibiotic</Technology><Technology id="740">Infusion</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J1P2</Code><Name>Carbapenems</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-28T06:40:46.000Z</LastModificationDate><ChangeDateLast>2019-01-08T00:00:00.000Z</ChangeDateLast><AddedDate>2014-11-12T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="29298" linkType="Company"&gt;Melinta Therapeutics&lt;/ulink&gt;, following the acquistion of the infectious disease business of &lt;ulink linkID="24653" linkType="Company"&gt;The Medicines Company&lt;/ulink&gt; (and its subsidiary &lt;ulink linkID="1066034" linkType="Company"&gt;Rempex Pharmaceuticals&lt;/ulink&gt;), has developed and launched Vabomere, a combination of &lt;ulink linkID="79502" linkType="Drug"&gt;vaborbactam&lt;/ulink&gt; (formerly Carbavance; RX-7009), a boron-containing beta-lactamase inhibitor and the carbapenem &lt;ulink linkID="3616" linkType="Drug"&gt;meropenem&lt;/ulink&gt; [&lt;ulink linkID="1309332" linkType="Reference"&gt;1309332&lt;/ulink&gt;], [&lt;ulink linkID="1506160" linkType="Reference"&gt;1506160&lt;/ulink&gt;], [&lt;ulink linkID="1986483" linkType="Reference"&gt;1986483&lt;/ulink&gt;], [&lt;ulink linkID="1995942" linkType="Reference"&gt;1995942&lt;/ulink&gt;]. Licensee &lt;ulink linkID="18053" linkType="Company"&gt;Menarini&lt;/ulink&gt; is also co-developing the drug in certain regions, including Europe [&lt;ulink linkID="2078685" linkType="Reference"&gt;2078685&lt;/ulink&gt;]. The product is indicated in the US for the treatment of patients aged 18 years and older with complicated urinary tract infections (cUTI), including pyelonephritis caused by designated susceptible bacteria [&lt;ulink linkID="1957413" linkType="Reference"&gt;1957413&lt;/ulink&gt;]. By November 2017, Vabomere had been launched in the US for use in  cUTI, including pyelonephritis [&lt;ulink linkID="1986483" linkType="Reference"&gt;1986483&lt;/ulink&gt;]. In November 2018, the European Commission (EC)  granted marketing authorization for Vabomere for  the treatment complicated intra-abdominal (cIAI) and cUTI, hospital-acquired pneumonia including ventilator associated pneumonia (HAP/VAP), bacteraemia that occurs in association with any of those infections, and infections due to aerobic gram-negative organisms where treatment options were limited [&lt;ulink linkID="2099214" linkType="Reference"&gt;2099214&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Rempex was  previously developing Vabomere as a combination of &lt;ulink linkID="79502" linkType="Drug"&gt;vaborbactam and RPX-2003&lt;/ulink&gt; [&lt;ulink linkID="1309332" linkType="Reference"&gt;1309332&lt;/ulink&gt;]; however, following the acquisition of Rempex by The Medicines Company in December 2013, the combination changed to vaborbactam plus meropenem [&lt;ulink linkID="1506160" linkType="Reference"&gt;1506160&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In February 2015, TMC noted that the company has acquired a portfolio of patents covering the composition of matter for Vabomere and its formulation and use. At that time, the compostion of matter patent was to expire in August 2031 and corresponding patents were pending in Europe and other foreign countries. Patents applications relating to the composition of matter and use in the US and foreign countries were also being prosecuted [&lt;ulink linkID="1641688" linkType="Reference"&gt;1641688&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In April 2016, the FDA granted Fast Track  review for cUTI [&lt;ulink linkID="1750414" linkType="Reference"&gt;1750414&lt;/ulink&gt;]. By February 2017, an NDA had been filed in the US for the treatment of cUTI based on data from the TANGO-1 study, and supported by interim results from the ongoing TANGO-2 trial. At that time, the filing was accepted for Priority Review by the FDA, and there were no plans to hold an advisory committee meeting to discuss the application [&lt;ulink linkID="1902071" linkType="Reference"&gt;1902071&lt;/ulink&gt;]. In August 2017, approval was granted in the US for the treatment of cUTI, including pyelonephritis, based on data from the phase III TANGO-1 study [&lt;ulink linkID="1957145" linkType="Reference"&gt;1957145&lt;/ulink&gt;], [&lt;ulink linkID="1957574" linkType="Reference"&gt;1957574&lt;/ulink&gt;]; by November 2017, launch had occurred in the US for that indication [&lt;ulink linkID="1986483" linkType="Reference"&gt;1986483&lt;/ulink&gt;]. In August 2018, the Centers for Medicare &amp;amp; Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for Vabomere when administered in the hospital inpatient setting [&lt;ulink linkID="2060068" linkType="Reference"&gt;2060068&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, the FDA    designated Vabomere as a Qualified Infectious Disease Product (QIDP), for iv use in six indications, including cUTI and intra-abdominal infections, hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia, and febrile neutropenia [&lt;ulink linkID="1515233" linkType="Reference"&gt;1515233&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In February 2016, TMC  stated that it expected pivotal data from TANGO-1 for an MAA submission; at the time of submission,  available data from TANGO-2 would also be submitted     [&lt;ulink linkID="1736164" linkType="Reference"&gt;1736164&lt;/ulink&gt;]. In July 2017, the EMA accepted an MAA for review for the treatment of cUTI [&lt;ulink linkID="1947914" linkType="Reference"&gt;1947914&lt;/ulink&gt;]. In January 2018, the EMA's CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the List of outstanding issue adopted on November 09, 2017 [&lt;ulink linkID="2012357" linkType="Reference"&gt;2012357&lt;/ulink&gt;]. In May 2018, an EMA decision was expected later that year [&lt;ulink linkID="2031865" linkType="Reference"&gt;2031865&lt;/ulink&gt;].  In September 2018, the CHMP of the EMA  adopted a positive opinion recommending  marketing authorization for the drug  for the treatment of  cIAI, cUTI (including pyelonephritis), hospital-acquired pneumonia (including ventilator associated pneumonia), bacteraemia that occurs in association with any of those infections and infections due to aerobic gram-negative organisms where treatment options were limited  [&lt;ulink linkID="2075186" linkType="Reference"&gt;2075186&lt;/ulink&gt;], [&lt;ulink linkID="2074831" linkType="Reference"&gt;2074831&lt;/ulink&gt;]. Later that month, final decision of marketing authorization by EC  was expected by November 2018. Following the approval from EC, the drug was planned to be granted marketing authorization in 28 countries of EU, Norway, Iceland and Liechtenstein [&lt;ulink linkID="2074831" linkType="Reference"&gt;2074831&lt;/ulink&gt;]; in November 2018, the EC had granted marketing authorization for the drug [&lt;ulink linkID="2099214" linkType="Reference"&gt;2099214&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In September 2016, &lt;ulink linkID="1042246" linkType="Company"&gt;Biomedical Advanced Research and Development Authority&lt;/ulink&gt; (BARDA) provided funding for a phase IIIb trial of Vabomere for  the treatment of Gram-negative infections in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia [&lt;ulink linkID="1798192" linkType="Reference"&gt;1798192&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, a phase III, multicenter, randomized, open-label study (&lt;ulink linkID="198401" linkType="Protocol"&gt;NCT02168946&lt;/ulink&gt;; TANGO-2; Rempex 506) of Vabomere versus best available therapy began in patients (expected n = 	150) with selected serious infections due to carbapenem-resistant enterobacteriaceae including cUTI, acute pyelonephritis, nosocomial pneumonia and/or bacteremia [&lt;ulink linkID="1575057" linkType="Reference"&gt;1575057&lt;/ulink&gt;]. In November 2014, the first patient was enrolled [&lt;ulink linkID="1608860" linkType="Reference"&gt;1608860&lt;/ulink&gt;]. In July 2017, data from an interim analysis were reported. Significant differences that favor Vabomere versus best available therapy (BAT) were observed. At that time,  the trial was stopped early, following recommendation from an independent Data and Safety Monitoring Board  (DSMB). The DSMB concluded that a risk-benefit analysis of available data would not support randomization of additional patients to the best available therapy comparator arm. The Company would continue to enroll patients into an amended, single-arm study protocol for Vabomere [&lt;ulink linkID="1947914" linkType="Reference"&gt;1947914&lt;/ulink&gt;]. In October 2017, further clinical data were presented at the 2017 IDWeek in San Diego, CA.In meropenem + vaborbactam versus BAT groups, 28 day all-cause mortality in patients with HABP/VABP and bacteremia combined was observed in 25 versus 44.4%, respectively. In patients with cUTI/AP, in meropenem + vaborbactam versus BAT groups, overall success rate at end-of-treatment (EOT) was 72.7 and 50%, and at test of cure (TOC) was 42.9 versus 50%, respectively; clinical cure rates were 72.7 versus 50 (at EOT) and 57.1 versus 50 (at TOC); microbial cure rates were 72.7 versus 50 (at EOT) and 50 versus 50 (at TOC), respectively. In patients with cIAI, clinical cure at TOC was 100 and 0% in meropenem + vaborbactam versus BAT groups, respectively. In meropenem + vaborbactam versus BAT groups, in patients with bacteremia, clinical cure rates were 50 versus 37.5 (EOT) and 58.3 versus 25% (TOC), respectively; microbial cure rates were 54.5 versus 50 (EOT), and 50 versus 37.5% (TOC), respectively [&lt;ulink linkID="1968137" linkType="Reference"&gt;1968137&lt;/ulink&gt;], [&lt;ulink linkID="1968488" linkType="Reference"&gt;1968488&lt;/ulink&gt;]. Further results were presented at the same conference. In meropenem+vaborbactam versus BAT groups, any treatment emergent adverse events (TEAEs) were reported in 84.6 versus 100%; drug related TEAEs were reported in 30.8 versus 40%; serious AEs were reported in 38.5 versus 50%; drug related AEs 0 versus 10%; treatment discontinuations due to TEAEs were reported in 15.4 versus 30% and renal related treatment related AEs were reported 7.7 versus 40% of patients, respectively [&lt;ulink linkID="1968151" linkType="Reference"&gt;1968151&lt;/ulink&gt;].  Further clinical data were presented at the same conference. A patient treated with meropenem + vaborbactam who carried KPC-3-producing K pneumoniae (4%) had a subsequent clinical isolate with a &amp;gt;/= 4-fold increase in meropenem + vaborbactam MIC (0.25 to 1 microg/ml), but remained susceptible after 6 days of therapy for acute pyelonephritis. A patients treated with ceftazidime-avibactam had a post-baseline clinical isolate of K pneumoniae with &amp;gt; 256-fold increase in MIC (0.5 to &amp;gt;128 microg/ml) compared to the baseline isolate following 7 days of therapy for a complicated intra-abdominal infection, and became resistant to ceftazidime-avibactam  [&lt;ulink linkID="1968156" linkType="Reference"&gt;1968156&lt;/ulink&gt;]. Further clinical data from subjects with renal impairment were presented at the same conference. In meropenem + vaborbactam and BAT groups (CRE-mMITT), the clinical cure rates were achieved by 40 and 25% (EOIVT) and 25 and 0% (TOC) of patients with CrCl of &amp;lt; 50 ml/min; 68.2 and 44.4% (EOIVT) and 75 and 44.4% (TOC) of patients with CrCl of &amp;gt;/= 50 ml/min, respectively. No evidence of decreased safety associated with meropenem + vaborbactam in patients with renal impairment [&lt;ulink linkID="1968077" linkType="Reference"&gt;1968077&lt;/ulink&gt;]. Further clinical data from mCRE-MITT population were presented at the same conference. In meropenem-vaborbactam versus BAT groups, across with all infection types, the clinical cure at EOT and TOC were 64.3 versus 33.3 (p = 0.04) and 57.1 versus 26.7% (p = 0.04), respectively; microbiologic cure at EOT and TOC reported were 64.3 versus 40 and 50 versus 33.3%, respectively; day-28 mortality reported was 17.9 versus 33.3% (p = 0.27), respectively; clinical failure or nephrotoxicity was observed in 32.1 versus 80%, (p &amp;lt; 0.001). Fewer TRAEs were reported in meropenem-vaborbactam versus BAT groups (24 versus 44.0%) [&lt;ulink linkID="1968051" linkType="Reference"&gt;1968051&lt;/ulink&gt;]. By November 2017, the trial was stopped early by an Independent Data and Safety Monitoring Board following a risk-benefit analysis of available data which was in favor of the drug [&lt;ulink linkID="1986483" linkType="Reference"&gt;1986483&lt;/ulink&gt;]. In April 2018, data was presented at the ECCMID 2018  held in Madrid, Spain. In May 2018,  aditional data from the trial and   publication were expected in 2018 [&lt;ulink linkID="2031865" linkType="Reference"&gt;2031865&lt;/ulink&gt;]. In April 2018, further clinical data were presented at the28th ECCMID in Madrid, SpainAcross all infection types in micro-MIIT population, meropenem-vaborbactam (n = 31) and BAT (n = 19) groups, clinical cure at EOT was 67.7 and 36.8%; clinical cure at TOC was 58.1 and 31.6%; microbiological cure at EOT was 67.7 and 42.1%; microbiological cure at TOC was 51.6 and 36.8%, and day 28 mortality was 16.1 and 26.3%, respectively [&lt;ulink linkID="2026374" linkType="Reference"&gt;2026374&lt;/ulink&gt;], [&lt;ulink linkID="2026685" linkType="Reference"&gt;2026685&lt;/ulink&gt;]. In October 2018, data from the study  were published. Data shown that the cure rates were  65.6%  versus  33.3% at end of therapy and 59.4%  versus  26.7% at TOC for vabomere and BAT, respectively. At day 28, all-cause mortality was 15.6% and 33.3% for vabomere and BAT respectively [&lt;ulink linkID="2078602" linkType="Reference"&gt;2078602&lt;/ulink&gt;], [&lt;ulink linkID="2079021" linkType="Reference"&gt;2079021&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2014, a randomized, multicenter, double-blind, double-dummy, parallel-group-assignment, safety/efficacy, phase III study (&lt;ulink linkID="197784" linkType="Protocol"&gt;NCT02166476&lt;/ulink&gt;; TANGO-1; Rempex 505) was initiated in the US in patients (n = 550) with cUTI and acute pyelonephritis. The trial would  compare the efficacy, safety, and tolerability of Vabomere with &lt;ulink linkID="29446" linkType="Drug"&gt;piperacillin/tazobactam&lt;/ulink&gt;. The primary endpoint was the efficacy measured at the end of iv treatment visit (based on FDA criteria) or at the test of cure visit (based on EMA criteria) [&lt;ulink linkID="1596032" linkType="Reference"&gt;1596032&lt;/ulink&gt;]. In November 2014, the first patient was enrolled [&lt;ulink linkID="1608860" linkType="Reference"&gt;1608860&lt;/ulink&gt;]. In May 2016, patient enrollment was complete [&lt;ulink linkID="1766632" linkType="Reference"&gt;1766632&lt;/ulink&gt;]. In June 2016, positive topline results were reported, which showed that the trial met both FDA and EMA  prespecified primary endpoints. Vabomere demonstrated  significant superiority versus piperacillin-tazobactam, with an overall success in 98.4% of patients in the intent-to-treat population treated with Vabomere compared with 94% of patients treated with piperacillin-tazobactam, using the FDA primary endpoint. Based on the EMA primary endpoint in the modified intent-to-treat population, microbiological eradication was 66.7% in the Vabomere group compared with 57.7% in the piperacillin-tazobactam group  [&lt;ulink linkID="1776092" linkType="Reference"&gt;1776092&lt;/ulink&gt;]. In October 2016, clinical data were presented at the 2016 IDWeek in New Orleans, LA. Overall success over 3 h (clinical cure; primary endpoint) was achieved by 189 of 192 and 171 of 182 patients receiving meropenem + vaborbactam and piperacillin + tazobactam, respectively. A total of 106 and 97 patients receiving meropenem + vaborbactam and piperacillin + tazobactam reported treatment emergent adverse events (TEAEs), respectively. At that time, the study was completed [&lt;ulink linkID="1866256" linkType="Reference"&gt;1866256&lt;/ulink&gt;]. In April 2017, further data were presented at the 27th ECCMID in Vienna, Austria.  Both microbiologically modified intent-to-treat (m-mITT)  and microbiologically evaluable (ME) population met non-inferiority  (EMA co-primary endpoint). In meropenem/vaborbactam and piperacillin/tazobactam groups, clinical cure at TOC was 90.6 and 86.3%, respectively, in m-mITT population, and 92.1 and 90.5%, respectively, in ME population. Overall, success at end of iv test (FDA primary endpoint) was observed in 98.4 and 94% of patients in meropenem/vaborbactam and piperacillin/tazobactam groups, respectively [&lt;ulink linkID="1920570" linkType="Reference"&gt;1920570&lt;/ulink&gt;]. Further clinical data were presented at the same conference. Meropenem+vaborbactam showed most potent in vitro activity against most of the Gram-negative organisms. Meropenem+vaborbactam and piperacillin/tazobactam showed similar clinical outcome rates by pathogen at end of iv treatment and test of cure visits. The overall trend in response for all pathogens at both time points were in favor of meropenem + vaborbactam over piperacillin + tazobactam [&lt;ulink linkID="1920442" linkType="Reference"&gt;1920442&lt;/ulink&gt;]. Further clinical data were presented at the same conference. The overall success rates at end-of iv treatment (EOIVT; microbiological modified intent-to-treat population) were found to be higher with meropenem/vaborbactam (n = 272) than piperacillin/tazobactam (n = 273), in patients with AP (97.5 versus 94.1%, respectively), cUTI and a removable source of infection (100 versus 92.1%, respectively), and in patients with cUTI and a non-removable source of infection (100 versus 95.3%, respectively). A similar safety profile was observed in both the groups  [&lt;ulink linkID="1920549" linkType="Reference"&gt;1920549&lt;/ulink&gt;]. In June 2017, further data in m-MITT population with concurrent bacteremia were presented at the 2017 ASM Microbe Conference in New Orleans, LA. In meropenem/vaborbactam and piperacillin/tazobactam group of patients with bacteremia (n = 12 and 15, respectively), the overall success rates at the end of iv therapy visit were 83.3 and 100%, respectively; and at the test of cure timepoint was 75.0 and 60.0%, respectively. With meropenem/vaborbactam, the most frequent adverse events were headache, diarrhea, infusion-site reaction and hypersensitivity [&lt;ulink linkID="1934334" linkType="Reference"&gt;1934334&lt;/ulink&gt;]. Further data of beta-lactamase producing patients in meropenem/vaborbactam and piperacillin/tazobactam group (n = 54 and 50, respectively) were presented at the same conference. In patients with beta-lactamase-producing isolates at baseline, the overall success rates at the end of iv therapy visit were similar between meropenem/vaborbactam and piperacillin/tazobactam groups, and between extended-spectrum beta-lactamases and non-extended-spectrum beta-lactamases. In patients with beta-lactamase-producing isolates at baseline, the overall success rates at the test of cure timepoint were higher in meropenem/vaborbactam group compared to piperacillin/tazobactam group [&lt;ulink linkID="1934101" linkType="Reference"&gt;1934101&lt;/ulink&gt;]. At the same conference, further data based on comorbidity severity were presented. In acute pyelonephritis patients with Charlson Comorbidity Score of &amp;gt;/= 3, the overall success rates favored meropenem/vaborbactam. In patients with cUTI with non-removable source of infection, Charlson Comorbidity Score did not affect the overall success rates [&lt;ulink linkID="1934193" linkType="Reference"&gt;1934193&lt;/ulink&gt;]. Further data based on by hospital and ICU length of stay were presented at the same conference. Regardless of the ICU stay during the study period, clinical cure rates at both timepoints were numerically higher in the meropenem/vaborbactam than piperacillin/tazobactam group. Regardless of the ICU stay during the study period, clinical cure rates at the end of iv therapy visit were numerically higher for both meropenem/vaborbactam than piperacillin/tazobactam groups than at test of cure timepoint [&lt;ulink linkID="1934334" linkType="Reference"&gt;1934322&lt;/ulink&gt;]. In October 2017, further clinical data were presented at the 2017 IDWeek in San Diego, CA. The MIC90 values of meropenem/vaborbactam against Enterobacteriaceae were in a range from &amp;lt;/= 0.06 to 32 microg/ml, while those with piperacillin/tazobactam were &amp;lt;/= 0.05 to &amp;gt; 64 microg/ml. Across the range of MICs, the overall clinical cure and microbial eradication rates of Enterobacteriaceae at end of iv treatment (EOIVT) were 98.2 and 97.6%, respectively in meropenem/vaborbactam and 95.5 and 92.2%, respectively in piperacillin/tazobactam [&lt;ulink linkID="1968055" linkType="Reference"&gt;1968055&lt;/ulink&gt;], [&lt;ulink linkID="1968488" linkType="Reference"&gt;1968488&lt;/ulink&gt;]. Further clinical data from subjects with renal impairment were presented at the same conference. In meropenem + vaborbactam and piperacillin + tazobactam groups (mITT; n = 374), the overall success was achieved by 100 and 90.9% (at EOIVT) and 61.9 and 65.2% (at TOC) of patients with CrCl of &amp;lt; 50 ml/min, respectively, and 98.2 and 94.3% (EOIVT) and 75.7 and 71.8% (TOC) of patients with CrCl &amp;gt;/= 50 ml/min, respectively. No evidence of decreased safety associated with meropenem + vaborbactam in patients with renal impairment  [&lt;ulink linkID="1968077" linkType="Reference"&gt;1968077&lt;/ulink&gt;]. In February 2018, further similar data were published [&lt;ulink linkID="2008824" linkType="Reference"&gt;2008824&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, registration studies were planned to be initiated in 2014 [&lt;ulink linkID="1506160" linkType="Reference"&gt;1506160&lt;/ulink&gt;]. By April 2014, the drug was 'phase III ready' [&lt;ulink linkID="1552922" linkType="Reference"&gt;1552922&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In October 2017, data from an open-label, single-dose, phase I study were presented in 41 subjects   with chronic renal impairment, including hemodialysis, against gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase-producing, carbapenem-resistant Enterobacteriaceae at the 2017 ID Week in San Diego, CA. Subjects (n = 41) received a single dose of meropenem and vaborbactam (1 g) in group 1 (mild renal impairment (estimated glomerular filtration rate [eGFR] of 60 to 89 ml/min/1.73 m2), 2 (moderate renal impairment [eGFR of 30 to &amp;lt;60 ml/min/1.73 m2]), 3 (severe renal impairment [eGFR &amp;lt;30 ml/min/1.73 m2]) and 4 (normal renal function [eGFR &amp;gt;90 ml/min/1.73 m2]); and group 5 (subjects with end-stage renal disease (ESRD) receiving hemodialysis therapy 3 times/week at least 3 months prior to Day 1 of study) received two doses (on-and off-dialysis).  Meropenem showed the Cmax of 27.5, 32.7, 40.5, 45.5, 44.7 and 47.7 microg/ml, respectively; AUC (0 to infinity) of 87.1, 112, 181, 397, 280 and 629 microg h/ml, respectively; AUC (0 to total) of 86.4, 111, 177, 362, 274 and 606 microg h/ml, respectively; t1/2 of 1.30, 1.43, 2.19, 6.10, 9.33 and 9.45 h, respectively; vaborbactam showed the Cmax of 27.8, 30.1, 42.4, 46.4, 56.5 and 50.1 microg/ml, respectively; AUC (0 to infinity) of 99.4, 116, 238, 781, 5220 and 1100 microg h/ml, respectively; AUC (0 to total) of 98, 114, 229, 532, 1640 and 533 microg h/ml, respectively; t1/2 of 1.65, 1.88, 3.45, 13.5, 79.3 and 55.2 microg h/ml, respectively, in subjects with normal, mild, moderate and severe impairment and end-stage renal disease off- and on-dialysis. Diarrhea, headache, abdominal pain and dermatitis were the most frequent TEAEs [&lt;ulink linkID="1968107" linkType="Reference"&gt;1968107&lt;/ulink&gt;].      &lt;/para&gt;&lt;para&gt;In July 2012, phase I trials were expected to begin in 3Q 2012 [&lt;ulink linkID="1309332" linkType="Reference"&gt;1309332&lt;/ulink&gt;]; by December 2013, phase I studies were completed [&lt;ulink linkID="1506160" linkType="Reference"&gt;1506160&lt;/ulink&gt;].  In September 2014, data were presented at the 54th ICAAC Meeting in Washington, DC. There were no changes in the pharmacokinetics of vaborbactam or meropenem alone and in combination. Vaborbactam alone and in combination with 1 or 2 g of meropenem was safe and well tolerated at all doses [&lt;ulink linkID="1589130" linkType="Reference"&gt;1589130&lt;/ulink&gt;]. In October 2014, further data were presented at the 2014 IDWeek in Philadelphia, PA. None of the patients reported serious adverse events; most of the adverse events were mild to moderate in severity. Maximum concentrations of vaborbactam and meropenem were seen at the end of 3 h infusion. Cmax and AUC values increased in a dose-dependent manner [&lt;ulink linkID="1598737" linkType="Reference"&gt;1598737&lt;/ulink&gt;]. In April 2015, further clinical data were also  presented at the 25th ECCMID in Copenhagen, Denmark. The respective, Cmax, Tmax, AUC (0 to 8), clearance, Vss and t1/2 values were 58.2 microg/ml, 2.98 h, 185.5 microg.h/ml, 11.1 l/h, 16.3 l and 1.03 h for meropenem and 59.0 microg/ml, 2.98 h, 204.2 microg.h/ml, 10.1 l/h, 17.6 l and 1.27 h for vaborbactam. The intrapulmonary penetration of meropenem and vaborbactam were approximately 63 and 53%, respectively [&lt;ulink linkID="1653598" linkType="Reference"&gt;1653598&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2017, preclinical data were presented at the 27th ECCMID in Vienna, Austria. Meropenem + varborbactam combination showed activity against most carbapenem-resistant Enterobacteriaceae isolates and strains carrying blaKPC genes that were MDR and prevalent in various European countries [&lt;ulink linkID="1920456" linkType="Reference"&gt;1920456&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  June 2016, preclinical data were presented at the 2016 ASM Microbe Conference in Boston, MA. Meropenem + verobactam (MIC50/90 were 0.03/0.06 microg/ml) inhibited 99.7% of Enterobacteriaceae isolates tested at &amp;lt;/= 1 microg/ml and all but four isolates (99.9%) were inhibited by this combination at &amp;lt;/= 4 microg/ml [&lt;ulink linkID="1772724" linkType="Reference"&gt;1772724&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, preclinical data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. Combination of RPX-7009 with meropenem significantly potentiated the activity of meropenem in bacterial killing in the kidneys infected with a meropenem-resistant strain of E coli [&lt;ulink linkID="1692777" linkType="Reference"&gt;1692777&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, preclinical data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA.  Meropenem/RPX-7009 showed MIC50/90 values of &amp;lt;/= 0.015/0.03, &amp;lt;/= 0.015/&amp;lt;/= 0.015, 0.03/0.03 and 0.06/1 microg/ml against Enterobacteriaceae, Escherichia coli, Klebsiella pneumonia, carbapenem-resistant Enterobacteriaceae, respectively [&lt;ulink linkID="1692660" linkType="Reference"&gt;1692660&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, preclinical data were presented at the 25th ECCMID in Copenhagen, Denmark. Maropenem was highly efficacious in the in vitro model of Pseudomonas aeruginosa strains with MIC value of 8 mg/l with no regrowth and no resistance development over 32 h study. Meropenen 2 g q8h by 3 h infusion was effective against two out o fthree strains but resistance was developed in the third strain with MIC of 8 mg/l [&lt;ulink linkID="1653527" linkType="Reference"&gt;1653527&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, preclinical data were presented at the 2014 IDWeek in Philadelphia, PA. Against all Enterobacteriaceae isolates tested, Vabomere (meropenem/vaborbactam) showed MIC50/90 values of &amp;lt;/= 0.25/1 and &amp;lt;/= 0.25/0.5 microg/ml at 4 and 8 microg/ml concentrations, respectively when compared with MIC50/90 values of &amp;lt;/= 0.25/8 microg/ml for meropenem alone. Overall, 80.3 and 90.8% of Klebsiella pneumonia isolates were inhibited by meropenem/RPX-7009 at fixed 4 and 8 microg/ml concentrations, while meropenem alone inhibited 21.1% of isolates [&lt;ulink linkID="1599532" linkType="Reference"&gt;1599532&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, preclinical data were presented at the 54th ICAAC Meeting in Washington, DC.  Meropenem/vaborbactam inhibited all Enterobacter cloacae isolates at inhibitor concentration of &amp;lt;/= 4 microg/ml and at &amp;lt;/= 0.06 microg/ml, all KPC-producing Escherichia coli strains were inhibited at 4 and 8 microg/ml of inhibitor, respectively. Vaborbactam did not showed any activity against-carbapenamase producing Enterobacteriaceae strains [&lt;ulink linkID="1589209" linkType="Reference"&gt;1589209&lt;/ulink&gt;]. Meropenem  with vaborbactam, both at a concentration of 2 g at exposures equivalent to human doses were active against all strains [&lt;ulink linkID="1589137" linkType="Reference"&gt;1589137&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2012, preclinical studies had shown show that Vabomere had activity against key Gram-negative pathogens, including E. coli, Klebsiella sp., Acinetobacter sp., and Pseudomonas aeruginosa [&lt;ulink linkID="1321603" linkType="Reference"&gt;1321603&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, preclinical data were presented at the Ninth GTC Meeting (Part I) in San Francisco, CA. Vabomere demonstrated stability against extended-spectrum beta-lactamases and several major carbapenemases including K pneumoniae carbapenemase and New Delhi metallo-beta-lactamase-1 expressed by K pneumonia and Enterobacter [&lt;ulink linkID="1309332" linkType="Reference"&gt;1309332&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In September 2016, TMC entered into a strategic partnership with  BARDA; under the terms of the agreement,  the authority  would provide $32 million in initial funding for a phase IIIb trial of Vabomere for  the treatment of Gram-negative infections in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia [&lt;ulink linkID="1798192" linkType="Reference"&gt;1798192&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, the EMA's PDCO adopted a positive opinion on  The Medicines Company's pediatric investigation plan (PIP) for meropenem/vaborbactam for  Gram-negative bacterial infections [&lt;ulink linkID="1697165" linkType="Reference"&gt;1697165&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2014, the BARDA granted Rempex with a contract under which the costs of several clinical and regulatory activities, aimed at obtaining US approval of the product for treating serious Gram-negative infections, would  be shared. The contract was for 5 years [&lt;ulink linkID="1527246" linkType="Reference"&gt;1527246&lt;/ulink&gt;], [&lt;ulink linkID="1699637" linkType="Reference"&gt;1699637&lt;/ulink&gt;]. In October 2014, BARDA put into effect a second option, increasing its intial financial support [&lt;ulink linkID="1641688" linkType="Reference"&gt;1641688&lt;/ulink&gt;]. In October 2015, Rempex was awarded a next option on the contract by BARDA with further financial support [&lt;ulink linkID="1699637" linkType="Reference"&gt;1699637&lt;/ulink&gt;]. In December 2015, BARDA increased the amount authorized under the third option [&lt;ulink linkID="1776092" linkType="Reference"&gt;1776092&lt;/ulink&gt;]. In February 2016, TMC noted that if all options were exercised by BARDA, the support would extend to approximately July 31, 2019 [&lt;ulink linkID="1739078" linkType="Reference"&gt;1739078&lt;/ulink&gt;]. By September 2016, 55.8 million had been obligated from the cost-sharing contract to support the development of Vabomere [&lt;ulink linkID="1798192" linkType="Reference"&gt;1798192&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, Rempex entered into a development and clinical supply agreement with &lt;ulink linkID="1010293" linkType="Company"&gt;Hospira&lt;/ulink&gt; for the clinical supply of vaborbactam. In September 2012, Rempex entered into a master services agreement with ACS Dobfar for additional clinical supplies. In February 2015, TMC expected to enter into a commercial supply agreement for the manufacture of both components of Vabomere [&lt;ulink linkID="1641688" linkType="Reference"&gt;1641688&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By December 2013, Rempex had entered into a master services agreement with &lt;ulink linkID="19909" linkType="Company"&gt;Sigma-Aldrich&lt;/ulink&gt; and a research and manufacturing services agreement with DSM Fine Chemicals for the supply of bulk drug substance for  vaborbactam  [&lt;ulink linkID="1641688" linkType="Reference"&gt;1641688&lt;/ulink&gt;]&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2018-01-08T00:00:00.000Z</StatusDate><Source id="1995942" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-01-08T00:00:00.000Z</StatusDate><Source id="1995942" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-01-08T00:00:00.000Z</StatusDate><Source id="1995942" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099214" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29298">Melinta Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2018-01-08T00:00:00.000Z</StatusDate><Source id="1995942" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2018-09-28T00:00:00.000Z</StatusDate><Source id="2078685" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2018-09-28T00:00:00.000Z</StatusDate><Source id="2078685" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2018-09-28T00:00:00.000Z</StatusDate><Source id="2078685" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2018-09-28T00:00:00.000Z</StatusDate><Source id="2078685" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2018-09-28T00:00:00.000Z</StatusDate><Source id="2078685" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1066034">Rempex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2013-12-04T00:00:00.000Z</StatusDate><Source id="1506160" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1066034">Rempex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1575057" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1066034">Rempex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2017-02-21T00:00:00.000Z</StatusDate><Source id="1902071" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1066034">Rempex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2017-08-29T00:00:00.000Z</StatusDate><Source id="1957145" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1066034">Rempex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1575057" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1066034">Rempex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2017-08-29T00:00:00.000Z</StatusDate><Source id="1957145" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1066034">Rempex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2017-11-29T00:00:00.000Z</StatusDate><Source id="1986483" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1066034">Rempex Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2017-07-25T00:00:00.000Z</StatusDate><Source id="1947914" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1066034">Rempex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2017-11-29T00:00:00.000Z</StatusDate><Source id="1986483" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1066034">Rempex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1575057" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1066034">Rempex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1575057" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29298">Melinta Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-01-08T00:00:00.000Z</StatusDate><Source id="1995942" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1066034">Rempex Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2017-07-25T00:00:00.000Z</StatusDate><Source id="1947914" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1066034">Rempex Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2017-07-25T00:00:00.000Z</StatusDate><Source id="1947914" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-09-28T00:00:00.000Z</StatusDate><Source id="2078685" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2018-09-28T00:00:00.000Z</StatusDate><Source id="2078685" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2018-09-28T00:00:00.000Z</StatusDate><Source id="2078685" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29298">Melinta Therapeutics Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2018-01-08T00:00:00.000Z</StatusDate><Source id="1995942" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29298">Melinta Therapeutics Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2018-01-08T00:00:00.000Z</StatusDate><Source id="1995942" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29298">Melinta Therapeutics Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-01-08T00:00:00.000Z</StatusDate><Source id="1995942" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="24653">The Medicines Company</OwnerCompany><Country id="US">US</Country><Indication id="3898">Complicated urinary tract infection</Indication><AwardedIndication>Treatment of cUTI</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-04-11T00:00:00.000Z</MileStoneDate><Source id="1750414" type="PR"/></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="24653">The Medicines Company</OwnerCompany><Country id="US">US</Country><Indication id="3898">Complicated urinary tract infection</Indication><AwardedIndication>Complicated urinary tract infections</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-02-21T00:00:00.000Z</MileStoneDate><Source id="1902071" type="PR"/></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="24653">The Medicines Company</OwnerCompany><Country id="US">US</Country><Indication id="137">Gram negative bacterium infection</Indication><AwardedIndication>Complicated intra-abdominal infections</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2014-01-13T00:00:00.000Z</MileStoneDate><Source id="1515233" type="PR"/></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="24653">The Medicines Company</OwnerCompany><Country id="US">US</Country><Indication id="3898">Complicated urinary tract infection</Indication><AwardedIndication>Complicated urinary tract infections</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2014-01-13T00:00:00.000Z</MileStoneDate><Source id="1515233" type="PR"/></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="24653">The Medicines Company</OwnerCompany><Country id="US">US</Country><Indication id="1815">Bacterial pneumonia</Indication><AwardedIndication>Hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2014-01-13T00:00:00.000Z</MileStoneDate><Source id="1515233" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00196"><Name>Beta lactamase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="18053">The Menarini Group</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="24653">The Medicines Company</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="29298">Melinta Therapeutics Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O</Smiles><Smiles>B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)Cc2cccs2)O</Smiles><Smiles>B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)Cc2cccs2)O.C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O</Smiles></StructureSmiles><Deals><Deal id="148425" title="BARDA to award Rempex Pharmaceuticals funding to develop Carbavance against MDR gram-negative infections                "/><Deal id="162426" title="BARDA to award MDCO funding to develop antibiotics including Carbavance for drug-resistant Gram-negative infections                "/><Deal id="244291" title="Melinta Therapeutics acquires Medicines Company's infectious disease business unit including Vabomere, Orbactiv and Minocin IV"/><Deal id="250137" title="Menarini to codevelop and commercialize Melinta's Vabomere, Orbactiv and Minocin in Europe, Asia-Pacific (excluding Japan), Korea, Australia and CIS (including Russia) "/></Deals><PatentFamilies><PatentFamily id="2224395" number="WO-2012021455" title="Cyclic boronic acid ester derivatives and therapeutic uses thereof"/><PatentFamily id="3427821" number="WO-2016172208" title="Methods of treating bacterial infections"/><PatentFamily id="4122603" number="WO-2018129479" title="Methods of treating bacterial infections"/><PatentFamily id="4461820" number="WO-2019070591" title="Methods of treating bacterial infections"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Menarini Group" id="18053"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Medicines Company" id="24653"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Melinta Therapeutics Inc" id="29298"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>